Status:

TERMINATED

PTNS vs Botox of Refractory OAB

Lead Sponsor:

Medstar Health Research Institute

Collaborating Sponsors:

University of Michigan

Methodist Urology Associates, Houston, Texas

Conditions:

Overactive Bladder (OAB)

Eligibility:

FEMALE

18+ years

Brief Summary

This is a prospective cohort study of women with overactive bladder OAB (dry or wet) who have failed 2 prior treatments, including behavioral modification, pelvic floor physical therapy, and/or OAB me...

Detailed Description

Prior to initiation of BTX or PTNS, patients will undergo a standardized evaluation including urodynamics study (UDS) if not previously done in the past year and pelvic organ prolapse quantification (...

Eligibility Criteria

Inclusion

  • Women with refractory OAB (dry or wet)
  • OAB will be defined by a positive response and bother of "somewhat, quite a bit, a great deal, or a very great deal" to question #3 or #8 on the OAB-q (see appendix B) regarding urinary urgency and urgency incontinence.
  • Refractory will be defined as failure of 2 prior treatments, including behavioral modification, pelvic floor physical therapy, and OAB medication (anticholinergics or mirabegron). Trial of 2 medications that did not improve symptoms after 2 weeks or could not be tolerated due to side effects will constitute 2 treatment failures.
  • Women with mixed urinary incontinence that is urge predominant will also be included.
  • Age ≥ 18 years
  • English speaking
  • Available for 1 year follow-up
  • Able to complete study questionnaires

Exclusion

  • Neurologic disease known to cause OAB including, but not limited to, Multiple sclerosis, Parkinson's disease, and Spinal Cord Injury.
  • Pregnancy by self-report or pregnancy test
  • Contraindication to PTNS and/or BTX
  • PTNS: Pacemaker
  • BTX: myasthenia gravis, allergy to BTX, urinary retention (post void residual \>200cc)
  • Planned surgery for pelvic floor disorder during the study period
  • Prior treatment with BTX, PTNS, or sacral nerve stimulation (SNS) for refractory OAB/urinary urge incontinence (UUI)

Key Trial Info

Start Date :

March 1 2015

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

December 1 2018

Estimated Enrollment :

150 Patients enrolled

Trial Details

Trial ID

NCT04451382

Start Date

March 1 2015

End Date

December 1 2018

Last Update

June 30 2020

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

MedStar Washington Hospital Center

Washington D.C., District of Columbia, United States, 20010

2

Columbia University

New York, New York, United States, 10032